Management of symptoms in children with autism spectrum disorders: A comprehensive review of pharmacologic and complementary-alternative medicine treatments

Journal of Developmental and Behavioral Pediatrics

Volumn 32, Issue 1, 2011, Pages 56-68

  Huffman, Lynne C ^a   Sutcliffe, Trenna L ^b   Tanner, Ima S D ^c   Feldman, Heidi M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Palo Alto Medical Foundation   (Mexico)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALTERNATIVE MEDICINE; AUTISM; CHILD; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; INFANT; MALE; METHODOLOGY; NEWBORN; PRESCHOOL CHILD; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COMPLEMENTARY THERAPIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651456267     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/DBP.0b013e3182040acf     Document Type: Review

References (136)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IVTR). Arlington, VA: American Psychiatric Publishing, Inc; 2000.
2. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009;58:1-20
3. Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics. 2007;120:1162-1182
4. Carbone PS, Farley M, Davis T. Primary care for children with autism. Am Fam Physician. 2010;81:453-460
5. Filipek PA, Steinberg-Epstein R, Book TM. Intervention for autistic spectrum disorders. NeuroRx. 2006;3:207-216
6. Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord. 2006;36:901-909
7. Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder J Autism Dev Disord. 2007, 37, 628-636
8. Levy SE, Hyman SL. Use of complementary and alternative treatments for children with autistic spectrum disorders is increasing. Pediatr Ann. 2003;32:685-691
9. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review Ann Clin Psychiatry. 2009, 21, 213-236.
10. Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest. 2008; 118:6-14
11. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008;17:787-801, viii-ix
12. Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2008;17:803-820, ix
13. Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry. 2008;16:97-112
14. Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother. 2007;8:1579-1603
15. Srinivasan P. A review of dietary interventions in autism. Ann Clin Psychiatry. 2009;21:237-247
16. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001;11:267-277
17. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial J Am Acad Child Adolesc Psychiatry. 2006,45,1196-1205.
18. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15:325-330
19. Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol. 2000;15:132-135
20. DeLong GR,Teague LA, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism Dev Med Child Neurol. 1998, 40, 551-562
21. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism Neuropsychopharmacology. 2005,30, 582-589.
22. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr. 2003;24:104-108
23. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders J Am Acad Child Adolesc Psychiatry. 2005,144,343-348.
24. Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism J Autism Dev Disord. 2005,135, 377-385.
25. Niederhofer H, Staffen W, Mair A. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Hum Psychopharmacol. 2003;18:389-393
26. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21:440-444
27. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, doubleblind, placebo-controlled trial. J Autism Dev Disord. 2001;31: 175-181
28. Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:426-432
29. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62:530-534
30. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 2002;23:225-230
31. Wasserman S, Iyengar R, Chaplin W, et al. Levetiracetam versus placebo in childhood and adolescent autism: A doubleblind placebo-controlled study, Int Clin Psychopharmacol. 2006, 21, 363-367
32. Akhondzadeh S, Erfani S, Mohammadi MR, et al. Cyproheptadine in the treatment of autistic disorder: a doubleblind placebo-controlled trial. J Clin Pharm Ther. 2004,129, 145-150.
33. Rossi PG, Posar A, Parmeggiani A, Pipitone E, D'Agata M. Niaprazine in the treatment of autistic disorder. J Child Neurol. 1999;14:547-550
34. King BH, Wright DM, Handen BL, et al. Double-blind, placebocontrolled study of amantadine hydrochloride in the treatment of children with autistic disorder J Am Acad Child Adolesc Psychiatry. 2001, 40, 658-665
35. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism J Child Neurol. 2000,15, 429-435.
36. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161:2115-2117
37. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13:79-82
38. Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger- Moore J, Ostrem JA. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study J Autism Dev Disord. 2006,136,1053-1064.
39. Bouvard MP, Leboyer M, Launay JM, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study Psychiatry Res. 1995,158,191-201.
40. Cazzullo AG, Musetti MC, Musetti L, Bajo S, Sacerdote P, Panerai A. Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur Neuropsychopharmacol. 1999;9:361-366
41. Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry. 1999;38:587-593
42. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry. 1995;34: 223-231
43. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry. 1997;36:1570-1578
44. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, van England H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry. 1995,152, 766-773.
45. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study, Biol Psychiatry. 1996,139,1023-1031.
46. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005,15, 869-884.
47. RUPP, Aman MG. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162:1361-1369
48. Anderson GM, Scahill L, McCracken JT, et al. Effects of shortand long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007,61, 545-550.
49. Arnold LE,Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003, 42, 1443-1450.
50. Canitano R. Self injurious behavior in autism: clinical aspects and treatment with risperidone. J Neural Transm. 2006;113: 425-431
51. Feroz-Nainar C, Roy M. Risperidone and late onset tics. Autism. 2006;10:302-307
52. Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc, Psychopharmacol. 2004,14, 39-47
53. Hellings JA, Zarcone JR, Reese RM, et al. A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord. 2006,136, 401-411.
54. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord. 1997;27:313-323
55. King B, Zwi K, Nunn K, Longworth J, Dossetor D. Use of risperidone in a paediatric population: an observational study. J Paediatr Child Health. 2003;39:523-527
56. Lindsay RL, Eugene Arnold L, Aman MG, et al. Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. J Intellect Dev Disabil. 2006; 31, 204-209.
57. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006,16, 575-587.
58. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry. 2002;41:140-147
59. Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6- month prospective data. Am J Psychiatry. 2004,161,1125-1127.
60. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry. 2003;64: 1039-1047
61. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002, 347, 314-321.
62. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997,136, 685-693.
63. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology, Am J Psychiatry. 2005,162,1142-1148
64. Mukaddes NM, Abali O, Gurkan K. Short-term efficacy and safety of risperidone in young children with autistic disorder (AD). World J Biol Psychiatry. 2004;5:211-214
65. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21:450-455
66. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry. 1998;37:372-376
67. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37:367-373
68. Rausch JL, Sirota EL, Londino DL, et al. Open-label risperidone for Asperger's disorder: negative symptom spectrum response. J Clin Psychiatry. 2005,166, 1592-1597.
69. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.Pediatrics., 2004,114, e634-e641.
70. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005,144,1137-1144.
71. Williams SK, Scahill L, Vitiello B, et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry. 2006,145, 431-439.
72. Zuddas A, Di Martino A, Muglia P, Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol. 2000,10, 79-90.
73. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman- Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol. 2002,122, 455-460.
74. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord. 2005;35:387-391
75. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry. 2004;65: 1531-1536
76. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41:921-927
77. Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study J Clin Psychiatry. 1998,159, 56-59.
78. Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19:165-169
79. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22: 574-579
80. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16:621-629
81. Geier DA, Geier MR. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett. 2006, 27, 833-838.
82. Dunn-Geier J, Ho HH, Auersperg E, et al. Effect of secretin on children with autism: a randomized controlled trial. Dev Med Child Neurol. 2000,142, 796-802.
83. Owley T, McMahon W, Cook EH, et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism, J Am Acad Child Adolesc Psychiatry. 2001, 40,1293-1299.
84. Unis AS, Munson JA, Rogers SJ, et al. A randomized, doubleblind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry. 2002, 41, 1315-1321.
85. Chez MG, Buchanan CP, Bagan BT, et al. Secretin and autism: a two-part clinical investigation, J Autism Dev Disord. 2000, 30, 87-94.
86. Coniglio SJ, Lewis JD, Lang C, et al. A randomized, doubleblind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr. 2001,138, 649-655
87. Corbett B, Khan K, Czapansky-Beilman D, et al. A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism. Clin Pediatr (Phila) 2001, 40, 327-331
88. Kern JK, Van Miller S, Evans PA, Trivedi MH. Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J Autism Dev Disord. 2002, 32, 153-160.
89. Levy SE, Souders MC, Wray J, et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Arch Dis Child. 2003,188, 731-736
90. Molloy CA, Manning-Courtney P, Swayne S, et al. Lack of benefit of intravenous synthetic human secretin in the treatment of autism J Autism Dev Disord. 2002,132, 545-551.
91. Roberts W, Weaver L, Brian J, et al. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebocontrolled trial. Pediatrics. 2001,1107, E71
92. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341:1801-1806
93. Honomichl RD, Goodlin-Jones BL, Burnham MM, Hansen RL, Anders TF. Secretin and sleep in children with autism. Child Psychiatry Hum Dev. 2002;33:107-123
94. Ratliff-Schaub K, Carey T, Reeves GD, Rogers MA. Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism. 2005;9:256-265
95. Toda Y, Mori K, Hashimoto T, et al. Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006, 128, 99-103.
96. Buitelaar JK, Dekker ME, van Ree JM, van Engeland H. A controlled trial with ORG 2766, an ACTH-(4 -9) analog, in 50 relatively able children with autism. Eur Neuropsychopharmacol. 1996,16, 13-19.
97. Lightdale JR, Hayer C, Duer A, et al. Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: A single-blinded, open-label pilot study. Pediatrics. 2001,108, E90
98. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266-1274
99. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol. 2004,114, 207-218.
100. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245-255
101. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures, Biol Psychiatry. 2007, 61, 538-544.
102. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995, 25 , 283-294.
103. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev. 2006;32:575-583
104. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc.Psychopharmacol. 2004,114, 49-56.
105. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551-553
106. Brudnak MA, Rimland B, Kerry RE, et al. Enzyme-based therapy for autism spectrum disorders-is it worth another look? Med Hypotheses. 2002,158, 422-428.
107. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32:585-589
108. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006; 36:741-752
109. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999;29:191-194
110. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders, J Child Neurol. 2002,117, 833-837
111. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: A double-blind placebo-controlled crossover study. J Clin Psychopharmacol. 2005, 25, 485-489.
112. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med. 2004;10:1033-1039
113. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res. 2006;19:53-62 (Pubitemid 43945611)
114. Johnson SM, Hollander E. Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry. 2003;64:848-849
115. Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol. 2007,36,152-158.
116. Findling RL, Maxwell K, Scotese-Wojtila L, Huang J, Yamashita T, Wiznitzer M. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord. 1997;27:467-478
117. Kuriyama S, Kamiyama M, Watanabe M, et al. Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Dev Med Child Neurol. 2002,144, 284-286.
118. Levine J, Aviram A, Holan A, Ring A, Barak Y, Belmaker RH. Inositol treatment of autism. J Neural Transm. 1997;104:307-310
119. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002;23:303-308
120. Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahydrobiopterin treatment in six children with autism- clinical and positron emission tomography data: a pilot study,Dev Med Child Neurol. 1997,139, 313-318.
121. Kern JK, Miller VS, Cauller PL, Kendall PR, Mehta PJ, Dodd M. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16:169-173
122. Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006, 67, 216-228.
123. Cornish E. Gluten and casein free diets in autism: a study of the effects on food choice and nutrition. J Hum Nutr Diet. 2002;15:261-269
124. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006;36:413-420
125. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003,18,113-118.
126. Knivsberg AM, Reichelt KL, Hoien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002;5:251-261
127. Arnold GL, Hyman SL, Mooney RA, Kirby RS. Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord. 2003;33:449-454
128. Lucarelli S, Frediani T, Zingoni AM, et al. Food allergy and infantile autism. Panminerva Med. 1995,137,137-141.
129. Jarusiewicz B. Efficacy of neurofeedback for children in the autistic spectrum: a pilot study. J Neurother. 2002;6:39-49
130. Scolnick B. Effects of electroencephalogram biofeedback with Asperger's syndrome. Int J Rehabil Res. 2005;28:159-163
131. West SL, King V, Carey TS, et al. Systems to Rate the Strength of Scientific Evidence. Rockville, MD: Agency for Healthcare Research and Quality; 2002.
132. Wilczynski SM. National Standards Report. Randolph, MA: National Autism Center; 2009
133. Guy W. NCDEU Assessment Manual for Psychopharmacology. 3rd ed. Rockville, MD: National Institute of Mental Health; 1976
134. Bech P. Rating scales for affective disorders: their validity and consistency. Acta Psychiatr Scand Suppl. 1981;295:1-101
135. Prien RF, Levine J. Research and methodological issues for evaluating the therapeutic effectiveness of antidepressant drugs. Psychopharmacol Bull. 1984;20:250-257
136. Beneke M, Rasmus W. "Clinical Global Impressions" (ECDEU): some critical comments. Pharmacopsychiatry. 1992;25:171-176